These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2511916)

  • 21. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
    Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
    Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
    Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
    Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
    [No Abstract]   [Full Text] [Related]  

  • 23. [Gastro-esophageal reflux. Treatment with Gaviscon].
    Ferrier JP; Chevrel B
    Med Chir Dig; 1978; 7(1):73-6. PubMed ID: 642629
    [No Abstract]   [Full Text] [Related]  

  • 24. The suppression of gastro-oesophageal reflux by alginates.
    Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
    Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gaviscon for gastro-oesophageal reflux in infants: a poorly effective treatment?
    Cresi F; Savino F; Marinaccio C; Silvestro L
    Arch Dis Child; 2006 Jan; 91(1):93. PubMed ID: 16371388
    [No Abstract]   [Full Text] [Related]  

  • 26. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
    Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
    Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vivo anti-reflux and raft properties of alginates.
    Lambert JR; Korman MG; Nicholson L; Chan JG
    Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gaviscon in reflux symptoms. Results of a drug monitoring study].
    Hutt HJ; Tauber O; Flach D
    Fortschr Med; 1990 Oct; 108(31):598-600. PubMed ID: 2258131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind controlled trial of 'Gaviscon' in patients with symptomatic gastro-oesophageal reflux.
    Barnardo DE; Lancaster-Smith M; Strickland ID; Wright JT
    Curr Med Res Opin; 1975; 3(6):388-91. PubMed ID: 1183220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
    Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
    Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children.
    Forbes D; Hodgson M; Hill R
    J Pediatr Gastroenterol Nutr; 1986; 5(4):556-9. PubMed ID: 3016226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastric pH and endoscopic appearance after Algicon administration.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():25-8; discussion 35-6. PubMed ID: 2511920
    [No Abstract]   [Full Text] [Related]  

  • 33. [Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension].
    Chevrel B
    Med Chir Dig; 1980; 9(6):535-9. PubMed ID: 6259459
    [No Abstract]   [Full Text] [Related]  

  • 34. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry.
    Zentilin P; Dulbecco P; Savarino E; Parodi A; Iiritano E; Bilardi C; Reglioni S; Vigneri S; Savarino V
    Aliment Pharmacol Ther; 2005 Jan; 21(1):29-34. PubMed ID: 15644042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial of gaviscon in the treatment of gastro-oesophageal reflux of infancy.
    Weldon AP; Robinson MJ
    Aust Paediatr J; 1972 Oct; 8(5):279-81. PubMed ID: 4349107
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative intragastric pH profile of Algicon versus Gaviscon.
    Stoddard CJ; Morgan GE
    Br J Clin Pract Suppl; 1989 Feb; 66():29-34; discussion 35-6. PubMed ID: 2556174
    [No Abstract]   [Full Text] [Related]  

  • 37. [Magnesium hydroxide and aluminum hydroxide in the treatment of gastroesophageal reflux].
    Iacono G; Carroccio A; Montalto G; Cavataio F; Ippolito S; Kazmierska I; Balsamo V
    Minerva Pediatr; 1991 Dec; 43(12):797-800. PubMed ID: 1798406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antacids.
    Hendrix TR
    Am Fam Physician; 1974 Mar; 9(3):184-6. PubMed ID: 4813464
    [No Abstract]   [Full Text] [Related]  

  • 39. [Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension].
    Uzan M; Uzan S; Sureau C; Richard-Berthe C
    Rev Fr Gynecol Obstet; 1988; 83(7-9):569-72. PubMed ID: 2848305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Can acid pocket-targeting alginate-antacid (Gaviscon Double Action) relieve upper gastrointestinal symptoms in gastro-oesophageal reflux disease?].
    Kim SE; Park MI
    Korean J Gastroenterol; 2014 Jun; 63(6):386-8. PubMed ID: 25097964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.